Why Skills-First Leadership Is Replacing the Ivy League Playbook in the C-Suite
05/23/2025
No Comments
The old prestige pyramid—where Ivy League degrees and blue-chip consulting backgrounds paved the way to the CEO seat—is cracking.
Immunogen, Inc. (IMGN) announced Thursday that biopharmaceutical giant AbbVie (ABBV) has agreed to be acquired in a deal worth $31.26 per share, valuing the company at approximately $10.1 billion. The news sent Immunogen shares soaring over 80% in pre-market trading, reaching over $29 per share.
The acquisition is expected to close in the middle of 2024, subject to regulatory approvals. Once completed, the deal will give AbbVie control of Immunogen’s flagship cancer therapy, Elahere, which is approved for treating platinum-resistant ovarian cancer. Elahere is considered a “first-in-class antibody-drug conjugate (ADC)” and has demonstrated significant efficacy in clinical trials.
AbbVie believes that acquiring Immunogen will strengthen its oncology portfolio and accelerate its growth in the solid tumor space. The company also sees Elahere as a potential blockbuster drug with the potential to generate significant sales in the coming years.
Investors reacted favorably to the news, with Immunogen shares surging over 80% in pre-market trading. The deal is expected to be accretive to AbbVie’s earnings in 2027.
The acquisition of Immunogen by AbbVie is a significant development in the biotechnology industry. The deal will give AbbVie control of a promising cancer therapy and strengthen its oncology portfolio. Immunogen shareholders will also likely benefit from the deal, receiving a significant share premium.
The acquisition is also a sign of the growing importance of ADCs in cancer treatment. ADCs are targeted therapies that combine an antibody with a cytotoxic drug. This allows the drug to be delivered directly to cancer cells, sparing healthy cells from damage. ADCs have shown promise in treating various cancers, and acquiring Immunogen will give AbbVie a strong foothold in this growing market.
The acquisition of Immunogen by AbbVie is a positive development for both companies. AbbVie will gain control of a promising cancer therapy, and Immunogen shareholders will receive a significant premium for their shares. The deal also shows the growing importance of ADCs in cancer treatment.
The old prestige pyramid—where Ivy League degrees and blue-chip consulting backgrounds paved the way to the CEO seat—is cracking.
Loud leaders once ruled the boardroom. Charisma was currency. Big talk drove big valuations.
But the CEOs who make history in downturns aren’t the ones with the deepest cuts
Companies invest millions in leadership development, yet many of their best executives leave within a few years. Why?
The most successful business leaders don’t just identify gaps in the market; they anticipate future needs before anyone else.
With technological advancements, shifting consumer expectations, and global interconnectedness, the role of business leaders
Following a distinguished Law Enforcement career Joe McGee founded The Securitatem Group to provide contemporary global operational specialist security and specialist security training products and services for private clients, corporate organisations, and Government bodies. They deliver a wide range of services, including complete end-to-end protection packages, close protection, residential security, protection drivers, and online and physical installations. They provide covert and overt investigations and specialist surveillance services with a Broad range of weapons and tactical-based training, including conflict management, risk and threat management, tactical training, tactical medicine, and command and control training.
Jay Wright, CEO and Co-Owner of Virgin Wines infectious energy, enthusiasm, passion and drive has been instrumental in creating an environment that encourages talent to thrive and a culture that puts the customer at the very heart of every decision-making process.
Fabio de Concilio is the visionary CEO & Chairman of the Board at Farmacosmo, a leading organization dedicated to mental health and community support services. With a deep commitment to identifying and meeting customer needs, Fabio ensures that high standards are maintained across the board.
Character Determines Destiny – so said Aristotle. And David CM Carter believes that more than anything else. For David, it has been numerous years of research into codifying Entelechy Academy’s 54 character qualities that underpin everything he stands for as a leader and teacher.
Leave us a message
Subscribe
Fill the form our team will contact you
Advertise with us
Fill the form our team will contact you
